Despite the promising effects of dual PI3K/mTOR inhibitors in cell lines, a recent clinical trial failed to demonstrate clinical benefit with NVP-BEZ235 as second line therapy in bladder cancer patients with locally advanced or metastatic disease [45]. Here, PIK3CD is linked to urinary bladder cancer.